Durable Mechanical Circulatory Support: JACC Scientific Statement (JACC October 2023-1)

Description

Despite advances in medical therapy for patients with stage C heart failure (HF), survival for patients with advanced HF is <20% at 5 years. Durable left ventricular assist device (dLVAD) support is an important treatment option for patients with advanced HF. Innovations in dLVAD technology have reduced the risk of several adverse events including pump thrombosis, stroke, and bleeding. Average patient survival is now similar to heart transplantation at 2 years with five-year dLVAD survival now approaching 60%. Unfortunately, greater adoption of dLVAD has not been realized due to delayed referral of patients to advanced HF centers, insufficient clinician knowledge of contemporary dLVAD outcomes including gains in quality-of-life, and de-prioritization of patients with dLVAD support waiting for heart transplantation. Despite these challenges, novel devices are on the horizon of clinical investigation, offering smaller size, permitting less invasive surgical implantation, and elimination of the percutaneous lead for power supply.

Editors
Editor-in-Chief
Valentin Fuster, MD, PhD, MACC

CME Editor
Ragavendra R. Baliga, MD

Author
Brent C. Lampert, DO, FACC

Important Dates
Date of Release: September 25, 2023
Term of Approval/Date of CME/MOC Expiration: September 24, 2024

Summary


Availability:	On-Demand
	Expires on Sep 24, 2024


Cost:	FREE


Credit Offered:	1 CME Credit 1 ABIM-MOC Point